Antibody Information
General Information of This Antibody
| Antibody ID | ANTI0VFQKL |
|||||
|---|---|---|---|---|---|---|
| Antibody Name | BCN-rituximab rit-v1a-145 |
|||||
| Synonyms |
BCN-rituximab rit-v1a-145
Click to Show/Hide
|
|||||
| Antigen Name | T-cell surface glycoprotein CD3 (CD3) |
Antigen Info | ||||
| Click to Show/Hide the Sequence Information of This Antibody | ||||||
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
Rit-v1a-145-204 [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
92.6 pM
|
|||
| Method Description |
The bispecific effect of hOKT3200 on human PBMC killing Raji B tumor cells. The bispecific and calculated EC50 values are shown in the legend.
|
||||
| In Vitro Model | Normal | PBMC cells | CVCL_0140 | ||
Rit-v1a-145-PF01 [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
100.3 pM
|
|||
| Method Description |
The bispecific effect of hOKT3200 on human PBMC killing RajiB tumor cells. The bispecific and calculated EC50 values are shown in the legend.
|
||||
| In Vitro Model | Normal | PBMC cells | CVCL_0140 | ||
Rit-v1a-145-PF02 [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
133.3 pM
|
|||
| Method Description |
The bispecific effect of hOKT3200 on human PBMC killing RajiB tumor cells. The bispecific and calculated EC50 values are shown in the legend.
|
||||
| In Vitro Model | Normal | PBMC cells | CVCL_0140 | ||